http://www.us-gsk.com/html/media-news/ GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news. http://us.gsk.com/html/media-news/pressreleases/2010/2010_pressrelease_10084.htm GlaxoSmithKline confirmed that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine currently being developed for the prevention of shingles. Wed, 14 July 2010 21:15:00 GMT http://us.gsk.com/html/media-news/pressreleases/2010/2010_pressrelease_10084.htm http://us.gsk.com/html/media-news/pressreleases/2010/2010_pressrelease_10083.htm GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE). A priority review designation is granted to drugs that, if approved, offer major advances in treatment or provide a treatment where no adequate therapy exists. The FDA has assigned belimumab a Prescription Drug User Fee Act (PDUFA) target date of 9 December 2010. Thu, 19 Aug 2010 11:30:00 GMT http://us.gsk.com/html/media-news/pressreleases/2010/2010_pressrelease_10083.htm http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10070.htm GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced today that a U.S. Food and Drug Administration (FDA) advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures. Wed, 11 Aug 2010 20:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10070.htm http://us.gsk.com/html/media-news/pressreleases/2010/2010_pressrelease_10080.htm Detailed pictures have been published today showing how a new type of experimental antibiotic can kill bacteria already resistant to existing treatments. The findings could ultimately help scientists to develop new antibiotics to tackle the bacteria responsible for many hospital and community-acquired infections. Thu, 5 Aug 2010 08:30:00 GMT http://us.gsk.com/html/media-news/pressreleases/2010/2010_pressrelease_10080.htm http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10068.htm GlaxoSmithKline [NYSE: GSK] announced today that the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval® [Influenza Virus Vaccine] allowing distribution in the U.S. to begin for the 2010-2011 flu season. Fri, 30 Jul 2010 14:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10068.htm http://us.gsk.com/html/media-news/pressreleases/2010/2010_pressrelease_10081.htm GlaxoSmithKline PLC (GSK) and Anacor Pharmaceuticals today announced that GSK has exercised its option to obtain an exclusive licence to develop and commercialise GSK2251052 (GSK '052), formerly known as AN3365. GSK '052 is a novel, systemic antibiotic derived from Anacor's boron chemistry platform. Thu, 29 Jul 2010 11:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2010/2010_pressrelease_10081.htm http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10067.htm GlaxoSmithKline [NYSE: GSK] today confirmed that it will implement a new system for evaluating and compensating its sales professionals beginning in 2011. Mon, 26 Jul 2010 19:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10067.htm http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10064.htm GlaxoSmithKline [NYSE: GSK] confirmed today that it will suspend enrollment of new patients in the Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) clinical trial at the request of the U.S. Food and Drug Administration (FDA) pending FDA review of recommendations from its Advisory Committee meeting July 13-14. Wed, 21 Jul 2010 16:15:00 GMT http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10064.htm http://www.gsk.com/investors/quarterly_results.htm Q2 EPS before major restructuring 2.6p (29.3p excluding pre-announced legal charge) Wed, 21 Jul 2010 12:00:00 GMT http://www.gsk.com/investors/quarterly_results.htm http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10061.htm A small number of Advair Diskus inhalers stolen from a GlaxoSmithKline distribution warehouse in 2009 have been found in some pharmacies. Fri, 16 July 2010 16:00:00 GMT http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10061.htm http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10060.htm Stiefel, a GSK company, today announced that the U.S. Food and Drug Administration (FDA) has approved VELTIN Gel for the topical treatment of acne vulgaris in patients 12 years and older. Fri, 16 July 2010 14:15:00 GMT http://us.gsk.com/html/media-news/pressreleases/2010/2010_us_pressrelease_10060.htm